AMINOGUANIDINE, AN INHIBITOR OF NITRIC-OXIDE FORMATION, FAILS TO PROTECT AGAINST INSULITIS AND HYPERGLYCEMIA-INDUCED BY MULTIPLE LOW-DOSE STREPTOZOTOCIN INJECTIONS IN MICE

被引：32

作者：

HOLSTAD, M ^{[1
]}

SANDLER, S ^{[1
]}

机构：

[1] UNIV UPPSALA,DEPT MED CELL BIOL,S-75123 UPPSALA,SWEDEN

来源：

AUTOIMMUNITY | 1993年 / 15卷 / 04期

关键词：

AMINOGUANIDINE; DIABETES MELLITUS; NITRIC OXIDE; STREPTOZOTOCIN;

D O I：

10.3109/08916939309115754

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

It has been suggested that pancreatic beta-cell destruction occurring during the process leading to insulin-dependent diabetes mellitus (IDDM) involves formation of nitric oxide (NO). We have presently studied the effect of aminoguanidine (AG), which has recently been reported to inhibit generation of NO induced by the cytokine interleukin-1 beta. AG currently counteracted IL-1 beta induced impairment of the glucose oxidation rate in rat pancreatic islets. Then we studied the effect of AG on the development of hyperglycemia and pancreatic insulitis in mice treated with multiple low dose injections of streptozotocin (40 mg/kg body-weight for five consecutive days). It was found that one daily intraperitoneal injection of AG (50 mg/kg body-weight) for 14 days failed to prevent the development of diabetes as well as insulitis following the streptozotocin injections. Furthermore, the mice treated with streptozotocin plus AG showed an increased mortality compared to mice treated with streptozotozin plus saline. Although the present data do not exclude a role for NO in IDDM, it raises concerns about the use of testing AG as therapeutic agent in IDDM.

引用

页码：311 / 314

页数：4

共 19 条

[1]

Corbett J.A., McDaniel M.L., Does nitric oxide mediate autoimmune destruction of β-cells? Possible therapeutic interventions in IDDM, Diabetes, 41, pp. 897-903, (1992)

[2]

Kolb H., Kolb-Bachofen V., Nitric oxide: A pathogenetic factor in autoimmunity, Immunol Today, 13, pp. 157-160, (1992)

[3]

Southern C., Schulster D., Green I.C., Inhibition of insulin secretion by interleukin-1 β and tumour necrosis factor-a via an L-arginine-dependent nitric oxide generating mechanism, FEBS Lett, 276, pp. 42-44, (1990)

[4]

Welsh N., Eizirik D.L., Bendtzen K., Sandler S., Interleukin-1β-induced nitric oxide production in isolated rat pancreatic islets requires gene transcription and may lead to inhibition of the Krebs cycle enzyme aconitase, Endocrinology, 129, pp. 3167-3173, (1991)

[5]

Sandler S., Eizirik D.L., Svensson C., Strandell E., Welsh M., Welsh N., Biochemical and molecular actions of interleukin-1 on pancreatic β-cells, Autoimmunity, 10, pp. 241-253, (1991)

[6]

Corbett J.A., Lancaster J.R., Sweetland M.A., McDaniel M.L., Interleukin-lβ-induced formation of EPR-detectable iron-nitrosyl complexes in islets of Langerhans. Role of nitric oxide in interleukin-lβ-induced inhibition of insulin secretion, J Biol Chem, 266, pp. 21351-21354, (1991)

[7]

Bergmann L., Kroncke K.-D., Suschek C., Kolb H., Kolb-Bachofen V., Cytotoxic action of IL-1β against pancreatic islets is mediated via nitric oxide formation and is inhibited by N<sup>G</sup>-monomethyl-L-aginine, FEBS Lett, 299, pp. 103-106, (1992)

[8]

Lukic M.L., Stosic-Grujicic S., Ostojic N., Chan W.L., Liew F.Y., Inhibition of nitric oxide generation affects the induction of diabetes by streptozocin in mice, Biochem Biophys Res Commun, 178, pp. 913-920, (1991)

[9]

Kolb H., Kiesel U., Kroncke K.-D., Kolb-Bachofen V., Suppression of low dose streptozotocin induced diabetes in mice by administration of a nitric oxide synthase inhibitor, Life Sci, 49, pp. PL-213-PL-217, (1991)

[10]

Like A.A., Rossini A.A., Streptozotocin-induced pancreatic insulitis: A new model of diabetes mellitus, Science, 193, pp. 415-417, (1976)

← 1 2 →